Active substance
Amoxicillin
- SFDA 70
- US FDA 74
- Health Canada 31
- US price lines 18
- NHS prices 11
- WHO EML 2
- Safety 28
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AMOXIL 250MG CAP. | 250 mg | Capsule · Oral use | 20 Blister | SAR 22.45 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| AMOXIL 500MG CAP. | 500 mg | Capsule · Oral use | 20 Blister | SAR 44.90 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| AMOXIL POWDER FOR ORAL SUSPENSION 125MG-5ML | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 16.80 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| AMOXIL POWDER FOR ORAL SUSPENSION FORTE 250MG-5ML | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 27.85 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| E-MOX 125MG DRY MIX. | 125 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 6.15 | Generic · Prescription | EIPICO | Valid |
| E-MOX 250MG DRY MIX. | 50 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 10.25 | Generic · Prescription | EIPICO | Valid |
| E-MOX 500MG CAPS | 500 mg | Capsule · Oral use | 16 Blister | SAR 10.25 | Generic · Prescription | EIPICO | Valid |
| GLOMOX 500MG CAP | 500 mg | Capsule · Oral use | 20 Blister | SAR 13.20 | Generic · Prescription | GLOBAL PHARMA | Valid |
| HYMOX 125MG-5ML POWDER FOR ORAL SUSPENSION | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 12.55 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| HYMOX 250MG CAPS | 250 mg | Capsule · Oral use | 20 Blister | SAR 20.20 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| HYMOX 250MG-5ML POWDER FOR ORAL SUSPENSION | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 25.05 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| HYMOX 500MG CAPS | 500 mg | Capsule · Oral use | 20 Blister | SAR 40.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| HYMOX 875 mg film-coated tablet | 875 mg | Film-coated tablet · Oral use | 14 Blister | SAR 49.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Juvamox | 50 mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 16.70 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Juvamox 500MG CAPSULES | 500 mg | Capsule · Oral use | 20 Blister | SAR 22.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MOXIDAD CAPSULES 250 MG | 250 mg | Capsule, hard · Oral use | 500 Blister | SAR 168.20 | Generic · Prescription | DAR ALDAWA | Valid |
| MOXIDAD CAPSULES 250MG | 250 mg | Capsule · Oral use | 20 Blister | SAR 7.30 | Generic · Prescription | DAR ALDAWA | Valid |
| MOXIDAD FORTE | 500 mg | Capsule · Oral use | 20 Blister | SAR 12.90 | Generic · Prescription | DAR ALDAWA | Valid |
| Moxidad forte | 500 mg | Capsule, hard · Oral use | 500 Blister | SAR 256.40 | Generic · Prescription | DAR ALDAWA | Valid |
| OMACILLIN 100MG-ML ORAL DROPS | 100 mg/ml | Oral drops · Oral use | 1 Bottle | SAR 9.80 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| REMOX 125MG-5ML SUSPENSION | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 13.55 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| REMOX 250 MG CAPSULES | 250 mg | Capsule · Oral use | 20 Blister | SAR 21.80 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| REMOX 250MG -5ML SUSPENSION | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 27.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| REMOX 500 MG CAPSULES | 500 mg | Capsule · Oral use | 20 Blister | SAR 43.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Remox | 250 mg | Capsule, hard · Oral use | 60 Blister | SAR 54.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
45 more — full table
Indications — CHI Daman Drug Formulary
ACUTE COUGH; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); ACUTE PYELONEPHRITIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - OTHER SALMONELLA INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-EVIDENCE BASED FIRST LINE TREATMENT STRATEGY; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT- H-PYLORI ERADICATION-SALVAGE THERAPIES; COMMUNITY ACQUIRED PNEUMONEA; DENTAL ABSCESS; LOWER URINARY TRACT INFECTIONS; MARGINAL ZONE LYMPHOMA; OSTEOMYELITIS; OTITIS MEDIA; PERICORONITIS; PHARYNGITIS; Pyogenic Arthritis; RECURRENT URINARY TRACT INFECTIONS (UTI); SINUSITIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AMOXICILLIN | 250MG; 500MG | capsule · oral | CHARTWELL RX | Prescription | 9 Feb 1976 |
| AMOXICILLIN | 250MG; 500MG | capsule · oral | CHARTWELL | Prescription | 3 Aug 1978 |
| AMOXIL | 250MG; 500MG | capsule · oral | US ANTIBIOTICS | Prescription | 2 Aug 1979 |
| AMOXIL | 125MG/5ML; 250MG/5ML; 50MG/ML | for suspension · oral | US ANTIBIOTICS | Prescription | 27 Nov 1979 |
| LAROTID | 125MG/5ML; 250MG/5ML | for suspension · oral | US ANTIBIOTICS | Prescription | 27 Nov 1979 |
| AMOXICILLIN | 250MG/5ML | for suspension · oral | CHARTWELL RX | Prescription | 1 Dec 1982 |
| AMOXICILLIN PEDIATRIC | 50MG/ML | for suspension · oral | CHARTWELL RX | Prescription | 1 Dec 1982 |
| AMOXICILLIN | 250MG; 125MG | tablet, chewable · oral | CHARTWELL RX | Prescription | 22 Dec 1992 |
| AMOXICILLIN | 250MG; 500MG | capsule · oral | SANDOZ | Prescription | 30 Sep 1994 |
| AMOXIL | 400MG/5ML | for suspension · oral | US ANTIBIOTICS | Prescription | 15 Apr 1999 |
| AMOXICILLIN | 500MG; 875MG | tablet · oral | CHARTWELL RX | Prescription | 18 Sep 2000 |
| AMOXICILLIN | 200MG/5ML; 400MG/5ML | for suspension · oral | CHARTWELL RX | Prescription | 4 Dec 2002 |
| AMOXICILLIN | 500MG; 875MG | tablet · oral | SANDOZ | Prescription | 13 Jul 2005 |
| AMOXICILLIN | 500MG; 875MG | tablet · oral | AUROBINDO | Prescription | 9 Nov 2005 |
| AMOXICILLIN | 250MG; 500MG | capsule · oral | AUROBINDO | Prescription | 9 Nov 2005 |
| AMOXICILLIN | 875MG | tablet · oral | HIKMA | Prescription | 29 Mar 2006 |
| AMOXICILLIN | 250MG/5ML; 125MG/5ML | for suspension · oral | HIKMA | Prescription | 19 Jun 2006 |
| AMOXICILLIN | 400MG/5ML; 200MG/5ML | for suspension · oral | HIKMA | Prescription | 19 Jun 2006 |
| AMOXICILLIN | 200MG/5ML; 400MG/5ML | for suspension · oral | AUROBINDO | Prescription | 28 Dec 2006 |
| AMOXICILLIN | 250MG; 500MG | capsule · oral | HIKMA PHARMS | Prescription | 5 Feb 2007 |
| AMOXICILLIN | 200MG/5ML; 400MG/5ML | for suspension · oral | SANDOZ | Prescription | 26 Mar 2007 |
| AMOXICILLIN | 125MG/5ML; 250MG/5ML | for suspension · oral | SANDOZ | Prescription | 26 Mar 2007 |
| AMOXICILLIN | 400MG/5ML | for suspension · oral | CHARTWELL RX | Prescription | 18 Jun 2007 |
| AMOXICILLIN | 125MG/5ML; 250MG/5ML | for suspension · oral | AUROBINDO PHARMA LTD | Prescription | 15 Sep 2014 |
| AMOXICILLIN | 250MG; 500MG | capsule · oral | MICRO LABS | Prescription | 24 Jun 2022 |
49 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-AMOXICILLIN | 02477726 | 500 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-AMOXICILLIN | 02537451 | 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | ANGITA PHARMA INC. |
| AMOXICILLIN | 02352753 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | SANIS HEALTH INC |
| AMOXICILLIN | 02352788 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | SANIS HEALTH INC |
| AMOXICILLIN | 02401509 | 500 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| AMOXICILLIN | 02401541 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | SIVEM PHARMACEUTICALS ULC |
| AMOXICILLIN CAPSULES BP | 02525348 | 250 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| AMOXICILLIN CAPSULES BP | 02525356 | 500 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| APO-AMOXI | 00628115 | 250 MG | CAPSULE · ORAL | APOTEX INC |
| APO-AMOXI | 00628123 | 500 MG | CAPSULE · ORAL | APOTEX INC |
| APO-AMOXI | 00628131 | 125 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | APOTEX INC |
| APO-AMOXI | 00628158 | 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | APOTEX INC |
| AURO-AMOXICILLIN | 02388073 | 250 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-AMOXICILLIN | 02388081 | 500 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-AMOXICILLIN | 02458586 | 125 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | AURO PHARMA INC |
| AURO-AMOXICILLIN | 02458594 | 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | AURO PHARMA INC |
| JAMP-AMOXICILLIN | 02433060 | 250 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP-AMOXICILLIN | 02433079 | 500 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP-AMOXICILLIN | 02535793 | 125 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | JAMP PHARMA CORPORATION |
| JAMP-AMOXICILLIN | 02535815 | 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | JAMP PHARMA CORPORATION |
| NOVAMOXIN | 00406716 | 500 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| NOVAMOXIN | 00406724 | 250 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| NOVAMOXIN | 00452130 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | TEVA CANADA LIMITED |
| NOVAMOXIN | 01934163 | 250 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | TEVA CANADA LIMITED |
| NOVAMOXIN | 02036355 | 250 MG | TABLET (CHEWABLE) · ORAL | TEVA CANADA LIMITED |
6 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMOXICILLIN 125 MG TAB CHEW | $0.20766 | per EA | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 125 MG/5 ML SUSP | $0.02112 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 125 MG/5 ML SUSP | $0.01757 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 125 MG/5 ML SUSP | $0.0228 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 200 MG/5 ML SUSP | $0.03621 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 200 MG/5 ML SUSP | $0.03944 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 200 MG/5 ML SUSP | $0.039 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 250 MG CAPSULE | $0.06871 | per EA | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 250 MG TAB CHEW | $0.30445 | per EA | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 250 MG/5 ML SUSP | $0.02438 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 250 MG/5 ML SUSP | $0.03044 | per ML | 23 Sep 2026 |
| US NADAC | AMOXICILLIN 250 MG/5 ML SUSP | $0.02452 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Amoxicillin 125mg/5ml oral suspension | £1.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 125mg/5ml oral suspension sugar free | £0.98 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 250mg capsules | £0.80 | 15 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 250mg capsules | £1.12 | 21 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 250mg/5ml oral suspension | £1.50 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 250mg/5ml oral suspension sugar free | £1.49 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 3g oral powder sachets sugar free | £54.74 | 2 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 500mg capsules | £0.85 | 15 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 500mg capsules | £1.19 | 21 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 500mg powder for solution for injection vials | £12.00 | 10 vial | 1 Oct 2026 |
| NHS Drug Tariff | Amoxicillin 500mg/5ml oral suspension sugar free | £9.40 | 100 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Acute pharyngitis; First choice: Periapical abscess without sinus; First choice: Acute sinusitis; First choice: Acute otitis media; First choice: Chronic obstructive pulmonary disease with acute exacerbation; First choice: Acute malnutrition in infants, children or adolescents (uncomplicated) [children]; First choice: Acute malnutrition in infants, children or adolescents (complicated) [children]; First choice: Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; First choice: Sepsis without septic shock (co-prescribed with gentamicin); Second choice: Bacterial meningitis
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc); 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) | Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection | Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate) (EMLc); 500 mg (scored) (as trihydrate) (EMLc) | Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) | Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection (EMLc); 500 mg in vial (as sodium) powder for injection (EMLc); 1 g in vial (as sodium) powder for injection (EMLc) | Oral > Solid > dosage form: 250 mg (as trihydrate) (EMLc); 500 mg (as trihydrate) (EMLc) | Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) (EML) - 5.1.6.1. Medicines for bacterial central nervous system infections · core
Second choice: Bacterial meningitis
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc); 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) | Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection | Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate) (EMLc); 500 mg (scored) (as trihydrate) (EMLc) | Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
Safety signals and safety-related labeling changes
- US FDA 17 Jul 2026 AUGMENTIN '125' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '125' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '200' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '200' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '250' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '250' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '250' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '400' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '400' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '500' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN '875' — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN ES-600 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Jul 2026 AUGMENTIN XR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 7 May 2026 PRAC signal: Encephalopathy
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Encephalopathy
Action for MAH: update of the product information: No
Combinations containing Amoxicillin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.